Living with Cystic Fibrosis

Lessons Jordan Learned Living with Cystic Fibrosis (CF) Lessons Jordan Learned Living with Cystic Fibrosis (CF)

See how Brian, Jordan, and Emily learned to live with
cystic fibrosis (CF)—without letting it define them.


Learn how these patients find ways to make Pulmozyme
and other CF treatments part of their day, every day

Selected Important Safety Information

Pulmozyme should not be used in patients who are allergic to any of its ingredients. Please see the continued Important Safety Information below, and see the Pulmozyme full Prescribing Information for additional Important Safety Information.

Make Pulmozyme part of your routine
Make Pulmozyme a part of every day—even when it's tough—even when you feel great. 
Integrating Pulmozyme into Brian's daily schedule helps him focus on what's important
Set aside time for Pulmozyme like you would taking your dog for a walk or preparing dinner—something that takes time, but isn't worth skipping.
Maximize your time by multitasking
Jordan figured out how to fit Pulmozyme into everyday life
Talk to your CF Care Team about coming up with a treatment routine that works best for you, especially when preparing to move away from home.
Catch up during treatments. Make the most of your time by emailing or texting friends while you take Pulmozyme.
Plan to make Pulmozyme and CF treatments a priority
Setting small goals, like taking Pulmozyme, can help you stay on track.
Emily makes taking Pulmozyme
a priority every day
Continue to be your own health advocate. Ask your CF Care Team any questions you may have about your medications and report any concerns or any side effects you may be experiencing.

Indication and Important Safety Information

Indication and Usage

Pulmozyme (dornase alfa) is indicated for daily administration along with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function.

In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring injectable antibiotics.

Important Safety Information

Pulmozyme should not be used in patients who are allergic to any of its ingredients.

Patients may experience the following when using Pulmozyme: change in or loss of their voice, discomfort in the throat, rash, chest pain, red watery eyes, runny nose, lowering of lung function, fever, indigestion, and shortness of breath. There have been no reports of severe allergic reactions caused by the administration of Pulmozyme. Mild to moderate hives and mild skin rash have been observed and have been short-lived.

Pediatric Use

The safety and effectiveness of Pulmozyme have been established in patients 5 years of age and older. While clinical trial data are limited in patients younger than 5 years of age, the use of Pulmozyme should be considered for pediatric CF patients who may experience potential benefit in lung function or who may be at risk of respiratory tract infection.

The safety of Pulmozyme given by daily inhalation for 2 weeks has been studied using 98 CF patients with 65 of them aged 3 months to <5 years (younger group) and 33 aged 5 years to <10 years (older group). The PARI BABY™ reusable nebulizer (which uses a face mask instead of a mouthpiece) was used in patients who were unable to show that they could breathe in or out using their mouth throughout the entire treatment period. Overall, the kind of side effects observed in children was similar to those seen in larger trials in older patients.

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

For additional Important Safety Information, please click here for the Pulmozyme full Prescribing Information. If you have questions, please discuss them with your CF Care Team.